FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136342505> ?p ?o ?g. }

• W3136342505 endingPage "483" @default.
• W3136342505 startingPage "483" @default.
• W3136342505 abstract "Rationale: Cystic fibrosis (CF), caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leads to impaired pancreatic function and therefore reduced intestinal absorption of lipids and fat-soluble vitamins especially in patients with CF developing pancreatic insufficiency (PI). Previous studies showed that CFTR modulator therapy with lumacaftor-ivacaftor (LUM/IVA) in Phe508del-homozygous patients with CF results in improvement of pulmonary disease and thriving. However, the effects of LUM/IVA on plasma concentration of the lipid soluble vitamins A and E remain unknown. Objectives: To investigate the course of plasma vitamin A and E in patients with CF under LUM/IVA therapy. Methods: Data from annual follow-up examinations of patients with CF were obtained to assess clinical outcomes including pulmonary function status, body mass index (BMI), and clinical chemistry as well as fat-soluble vitamins in Phe508del-homozygous CF patients before initiation and during LUM/IVA therapy. Results: Patients with CF receiving LUM/IVA improved substantially, including improvement in pulmonary inflammation, associated with a decrease in blood immunoglobulin G (IgG) from 9.4 to 8.2 g/L after two years (p < 0.001). During the same time, plasma vitamin A increased significantly from 1.2 to 1.6 µmol/L (p < 0.05), however, levels above the upper limit of normal were not detected in any of the patients. In contrast, plasma vitamin E as vitamin E/cholesterol ratio decreased moderately over the same time from 6.2 to 5.5 µmol/L (p < 0.01). Conclusions: CFTR modulator therapy with LUM/IVA alters concentrations of vitamins A and vitamin E in plasma. The increase of vitamin A must be monitored critically to avoid hypervitaminosis A in patients with CF." @default.
• W3136342505 created "2021-03-29" @default.
• W3136342505 creator A5015271937 @default.
• W3136342505 creator A5025750026 @default.
• W3136342505 creator A5026812496 @default.
• W3136342505 creator A5037784656 @default.
• W3136342505 creator A5042296967 @default.
• W3136342505 creator A5045061445 @default.
• W3136342505 creator A5047681000 @default.
• W3136342505 creator A5057646008 @default.
• W3136342505 creator A5077180702 @default.
• W3136342505 creator A5082640825 @default.
• W3136342505 creator A5091360482 @default.
• W3136342505 date "2021-03-19" @default.
• W3136342505 modified "2023-10-18" @default.
• W3136342505 title "CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis" @default.
• W3136342505 cites W1589654967 @default.
• W3136342505 cites W1711216671 @default.
• W3136342505 cites W1852336787 @default.
• W3136342505 cites W1935841659 @default.
• W3136342505 cites W1985718361 @default.
• W3136342505 cites W2020695495 @default.
• W3136342505 cites W2027024393 @default.
• W3136342505 cites W2028279889 @default.
• W3136342505 cites W2045947845 @default.
• W3136342505 cites W2047779780 @default.
• W3136342505 cites W2050781276 @default.
• W3136342505 cites W2054456868 @default.
• W3136342505 cites W2055988472 @default.
• W3136342505 cites W2063918246 @default.
• W3136342505 cites W2067766530 @default.
• W3136342505 cites W2069107365 @default.
• W3136342505 cites W2080501886 @default.
• W3136342505 cites W2085642903 @default.
• W3136342505 cites W2085861288 @default.
• W3136342505 cites W2085902602 @default.
• W3136342505 cites W2086938285 @default.
• W3136342505 cites W2093236267 @default.
• W3136342505 cites W2099449365 @default.
• W3136342505 cites W2105268524 @default.
• W3136342505 cites W2115508558 @default.
• W3136342505 cites W2121996960 @default.
• W3136342505 cites W2132756075 @default.
• W3136342505 cites W2137731450 @default.
• W3136342505 cites W2147849439 @default.
• W3136342505 cites W2156757210 @default.
• W3136342505 cites W2161050543 @default.
• W3136342505 cites W2161730987 @default.
• W3136342505 cites W2165613788 @default.
• W3136342505 cites W2300224114 @default.
• W3136342505 cites W2339321981 @default.
• W3136342505 cites W2515864729 @default.
• W3136342505 cites W2564673452 @default.
• W3136342505 cites W2595297484 @default.
• W3136342505 cites W2611432018 @default.
• W3136342505 cites W2624387478 @default.
• W3136342505 cites W2766423847 @default.
• W3136342505 cites W2779938552 @default.
• W3136342505 cites W2782678117 @default.
• W3136342505 cites W2791688327 @default.
• W3136342505 cites W2792598062 @default.
• W3136342505 cites W2887849896 @default.
• W3136342505 cites W2890802504 @default.
• W3136342505 cites W2900314843 @default.
• W3136342505 cites W2951436114 @default.
• W3136342505 cites W2982296199 @default.
• W3136342505 cites W2985405196 @default.
• W3136342505 cites W2995885749 @default.
• W3136342505 cites W2996441745 @default.
• W3136342505 cites W2997674649 @default.
• W3136342505 cites W3006632303 @default.
• W3136342505 cites W3033256788 @default.
• W3136342505 cites W3036692520 @default.
• W3136342505 cites W3132503015 @default.
• W3136342505 cites W4211056322 @default.
• W3136342505 cites W4211144794 @default.
• W3136342505 cites W4214721068 @default.
• W3136342505 cites W4252631293 @default.
• W3136342505 doi "https://doi.org/10.3390/antiox10030483" @default.
• W3136342505 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8003491" @default.
• W3136342505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33808590" @default.
• W3136342505 hasPublicationYear "2021" @default.
• W3136342505 type Work @default.
• W3136342505 sameAs 3136342505 @default.
• W3136342505 citedByCount "16" @default.
• W3136342505 countsByYear W31363425052021 @default.
• W3136342505 countsByYear W31363425052022 @default.
• W3136342505 countsByYear W31363425052023 @default.
• W3136342505 crossrefType "journal-article" @default.
• W3136342505 hasAuthorship W3136342505A5015271937 @default.
• W3136342505 hasAuthorship W3136342505A5025750026 @default.
• W3136342505 hasAuthorship W3136342505A5026812496 @default.
• W3136342505 hasAuthorship W3136342505A5037784656 @default.
• W3136342505 hasAuthorship W3136342505A5042296967 @default.
• W3136342505 hasAuthorship W3136342505A5045061445 @default.
• W3136342505 hasAuthorship W3136342505A5047681000 @default.
• W3136342505 hasAuthorship W3136342505A5057646008 @default.
• W3136342505 hasAuthorship W3136342505A5077180702 @default.

• next